Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: The analysis suggests the potentially harmful effect of Celebrex dosage is most pronounced in higher-risk patients, researchers said at the American College of Cardiology scientific meeting. "Patients at low cardiovascular risk should take some level of comfort," said Dr. Scott Solomon, lead researcher of the National Cancer Institute-sponsored analysis. "That wasn't so clear previously." Doctors should exercise caution in prescribing the drug, generally known as celecoxib, in high-risk patients, said Solomon, whose analysis was also published online in the journal Circulation. Celebrex belongs to a class of pain drugs known as cox-2 inhibitors and is the only such drug still on the market in the United States. Merck and Co Inc withdrew its widely used cox-2 drug, Vioxx, from the market in 2004 after a study showed it doubled the risk of heart attack and stroke in long- term users. Another cox-2 inhibitor from Pfizer called Bextra was also pulled from the U.S. market due to safety concerns. While the analysis sheds light on how the drug should be used, Solomon said he could not judge whether the data lift the cloud over this class of drugs. The six trials involving a total of 7,950 patients all studied Celebrex against a placebo for uses other than arthritis. Patients received either 400 milligrams once a day, 200 mg twice a day, or 400 mg twice a day. The primary goal of the pooled analysis was an assessment of the combined risk of cardiovascular death, heart attack, stroke, heart failure or events involving blood clots. Researchers found the heart risk was lowest at the 400 mg daily dose. They found nearly a two-fold risk of adverse heart events with the 200 mg twice daily dose and that jumped to about a three-fold risk at the 400 mg twice daily dose. "Even 400 mg once a day showed elevated risk" in the high-risk population, Solomon said, adding he could not extrapolate whether doses lower than 400 mg cut risk further. The increased risk was not affected by aspirin use, researchers said. "Most of the data used in this pooled analysis have previously been published and are consistent with what we already know about the cardiovascular risks of Celebrex and other prescription arthritis pain relievers," said Gail Cawkwell, Pfizer's executive medical director. "The analysis doesn't provide any new conclusions on the FDA-approved doses of Celebrex, including the most commonly prescribed dose of 200 mg daily," she said. Dr. Steven Nissen of the Cleveland Clinic, who has a study on lower doses underway, added: "There aren't long-term randomized placebo-controlled trials for that dose, The only way we're ever going to answer these questions is with good randomized prospective data," he said. "We'll tell it like it is when the data is in." Claim: Celebrex risky in high-risk patients, study finds.

Answer: Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain drug said on Monday.

Question: Paragraph: The baby died in November after being hospitalized for three months, the Department of Health said Wednesday. The last pediatric death related to pertussis, or whooping cough, was in 2013. The department's preliminary data shows that in 2019 there were 25 cases of pertussis in babies less than 6 months. Of those, eight were hospitalized, and two of the hospitalized cases were severe. Anyone can get pertussis, but it is most severe in infants, according to health officials. They are emphasizing the importance of vaccination, especially during pregnancy, to help prevent pertussis. Kristen Ehresmann, the department's director of infectious disease, said the tetanus, diphtheria and acellular pertussis, or Tdap, vaccine is recommended during the third trimester of each pregnancy. When the Tdap vaccine is given during pregnancy, the mother's body creates antibodies to fight off the pertussis bacteria, Ehresmann said. Some of those antibodies are passed to the baby before birth and offer short-term protection until the baby can be vaccinated. Claim: Infant death related to whooping cough in Minnesota.

Answer: Minnesota health officials say the death of an infant has been linked to whooping cough.

Question: Paragraph: "The story does not mention costs, but it is understandable that pricing may not be available with a drug so early in development. The story does a good job of quantifying the benefits of treatment in absolute terms by providing the actual number of months with no new lesions for both the new drug group and the standard treatment group. The story mentions that potential harms of the drug include a drop in white blood cells, back pain and fatigue. The story adequately describes the design of the current study. The story accurately describes the study as ""small"" and ""preliminary."" The story does not overstate the seriousness or prevalence of melanoma. The story quotes one independent expert in addition to a representative of the company. The story does mention that ""there are very few drugs available for people with advanced melanoma."" However, the story could have elaborated on the available alternatives and how this new drug may fit in with the existing options. The story clearly states that the drug is in very early stages of development and has not yet been submitted for approval. The story clearly states that the drug is new. There is no way to know if the story relied on a press release as the sole source of information." Claim: Skin cancer drug said to show promise

Answer:
Melanoma is the most deadly form of skin cancer. If caught early, it is highly treatable. If found in advanced stages, the 5 year survival drops significantly. This story reports on the results of a small pilot study showing a benefit in treating advanced stage melanomausinga new class of drug. This short story does a great job of informing the reader while using a minimum of words (only 343). The story adequately represents the availability and novelty of the new drug. The story accurately describes the strength of the available evidence by correctly describing the currentstudy as "small" and "preliminary." The story does a good job of quantifying the benefits of treatment in absolute terms by providing the actual number of months with no new lesions for both the new drug group and the standard treatment group. Finally, the story does mention that "there are very few drugs available for people with advanced melanoma." However, the story could have elaborated on the available alternatives and how this new drug may fit in with the existing options.